Analysis of Velmanase Alfa (Lamzede®)'s Effects in the Body of Children With Alpha-Mannosidosis Under the Age 3

Inclusion Criteria

• •Subjects with the provision of informed consent from their legal guardians (LAR)
• •Have a confirmed diagnosis of alpha mannosidosis
• •Have initiated treatment with velmanase alfa between birth to at least six weeks before turning 3 years of age
• •Have information on the disease marker GlcNAc(Man)2 obtained:
• •before velmanase treatment initiation (ideally max 6 month before), and at least one post-treatment sample, collected following at least six weeks of treatment.
• •\- Participants treated with Lamzede, 1 mg/kg body weight, via weekly intravenous infusions.